Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: Wall Street's top stories at midday » 12:49
05/06/20
05/06
12:49
05/06/20
12:49
DIS

Disney

$101.42 /

+0.16 (+0.16%)

, GM

General Motors

$22.21 /

+0.97 (+4.57%)

, ATVI

Activision Blizzard

$72.14 /

+3.61 (+5.27%)

, EA

Electronic Arts

$113.89 /

-5.71 (-4.77%)

, CVS

CVS Health

$61.81 /

+0.66 (+1.08%)

, BYND

Beyond Meat

$123.25 /

+23.11 (+23.08%)

, ODP

Office Depot

$2.15 /

+0.29 (+15.59%)

, SHOP

Shopify

$725.24 /

+37.81 (+5.50%)

, MELI

MercadoLibre

$736.98 /

+116.5 (+18.78%)

, INGN

Inogen

$42.50 /

-10.21 (-19.37%)

, PINS

Pinterest

$18.57 /

-2.27 (-10.89%)

, MAT

Mattel

$8.15 /

-0.45 (-5.23%)

The S&P and Dow have…

Open Full Text

ShowHide Related Items >><<
DIS Disney
$101.42 /

+0.16 (+0.16%)

05/06/20 Loop Capital
Disney price target lowered to $120 from $125 at Loop Capital
05/06/20 JPMorgan
Disney opening in Shanghai first of many catalysts, says JPMorgan
05/06/20 Morgan Stanley
Morgan Stanley highlights three Disney 'unknowns that remain largely unknown'
05/06/20 BMO Capital
Disney price target lowered to $140 from $150 at BMO Capital
GM General Motors
$22.21 /

+0.97 (+4.57%)

05/06/20 Morgan Stanley
Morgan Stanley says GM profit 'far above' expectations, liquidity 'very strong'
04/27/20 Morgan Stanley
General Motors stopping cash return 'an early buy signal,' says Morgan Stanley
04/15/20
Fly Intel: Top five analyst initiations
04/14/20 Goldman Sachs
Ford, GM started at Neutral at Goldman Sachs on anticipated cash burn
ATVI Activision Blizzard
$72.14 /

+3.61 (+5.27%)

05/06/20 Morgan Stanley
Activision Blizzard price target raised to $76 from $70 at Morgan Stanley
05/06/20 Wedbush
Activision Blizzard price target raised to $84 from $76 at Wedbush
05/06/20 Oppenheimer
Activision Blizzard price target raised to $73 from $68 at Oppenheimer
05/06/20 Cowen
Activision Blizzard price target raised to $66 from $60 at Cowen
EA Electronic Arts
$113.89 /

-5.71 (-4.77%)

05/06/20 Needham
Electronic Arts price target raised to $135 from $120 at Needham
05/06/20 Wedbush
Electronic Arts price target raised to $145 from $135 at Wedbush
05/06/20 Cowen
Electronic Arts price target raised to $129 from $119 at Cowen
CVS CVS Health
$61.81 /

+0.66 (+1.08%)

03/25/20 RBC Capital
CVS Health price target lowered to $81 from $85 at RBC Capital
03/24/20 Cowen
CVS Health outperformance should continue post-virus, says Cowen
03/12/20 Canaccord
Livongo Health weakness a buying opportunity, says Canaccord
02/20/20 Stephens
Stephens watching near-term MCO stock reactions after Bloomberg's 'rough' debate
BYND Beyond Meat
$123.25 /

+23.11 (+23.08%)

05/06/20 Goldman Sachs
Goldman Sachs reduces 2020-22 revenue estimates for Beyond Meat after Q1 report
05/06/20 DA Davidson
Beyond Meat price target raised to $83 from $62 at DA Davidson
05/06/20 Barclays
Beyond Meat reported strong Q1 results, says Barclays
05/01/20
Fly Intel: Top five analyst downgrades
ODP Office Depot
$2.15 /

+0.29 (+15.59%)

04/30/20 Sidoti
Office Depot initiated with a Buy at Sidoti
08/20/19 BofA
Office Depot price target lowered to $1.20 from $2 at BofA/Merrill
05/09/19
Fly Intel: Top five analyst downgrades
05/09/19 BofA
BofA/Merrill double downgrades Office Depot to Underperform after Q1 report
SHOP Shopify
$725.24 /

+37.81 (+5.50%)

05/04/20 Cleveland Research
Shopify partners finished Q1 slightly above plan, says Cleveland Research
04/30/20
Fly Intel: Top five analyst downgrades
04/30/20 Canaccord
Canaccord downgrades Shopify to Hold from Buy on 'extreme' valuation
04/30/20 Canaccord
Shopify downgraded to Hold from Buy at Canaccord
MELI MercadoLibre
$736.98 /

+116.5 (+18.78%)

05/06/20 Credit Suisse
MercadoLibre price target raised to $770 from $720 at Credit Suisse
05/06/20 Citi
MercadoLibre upgraded to Buy from Neutral at Citi
05/06/20 Barclays
MercadoLibre price target raised to $810 from $620 at Barclays
05/06/20 Stifel
MercadoLibre price target raised to $750 from $655 at Stifel
INGN Inogen
$42.50 /

-10.21 (-19.37%)

01/13/20 William Blair
Inogen's softer than expected DTC demand a surprise, says William Blair
11/06/19 Needham
Inogen upgraded to Buy from Hold at Needham
11/06/19 Needham
Inogen upgraded to Buy from Hold at Needham
09/12/19 Piper Sandler
Piper confident in Inogen's double-digit growth potential for 2020
PINS Pinterest
$18.57 /

-2.27 (-10.89%)

05/06/20 DA Davidson
Pinterest downgraded to Neutral from Buy at DA Davidson
05/06/20 Baird
Pinterest price target lowered to $20 from $23 at Baird
05/06/20 DA Davidson
Pinterest downgraded to Neutral from Buy at DA Davidson
05/06/20 Nomura Instinet
Pinterest price target lowered to $28 from $32 at Nomura Instinet
MAT Mattel
$8.15 /

-0.45 (-5.23%)

05/01/20 JPMorgan
JPMorgan lowers Mattel target to $11, removed from Analyst Focus List
04/21/20 Goldman Sachs
Mattel price target lowered to $10 from $14 at Goldman Sachs
04/17/20 Wolfe Research
Mattel initiated with an Outperform at Wolfe Research
04/16/20 Berenberg
Mattel initiated with a Hold at Berenberg
Hot Stocks
Inogen withdraws FY20 guidance » 16:32
05/05/20
05/05
16:32
05/05/20
16:32
INGN

Inogen

$52.76 /

+2.47 (+4.91%)

Inogen is withdrawing its…

Inogen is withdrawing its previously announced full year 2020 guidance issued on February 25, 2020 as the Company is unable to estimate the scope, duration, and impact of the COVID-19 PHE for full year 2020. The Company believes it could continue to see a decline in sales in its direct-to-consumer channel until patient mobility and consumer confidence increases. The Company also believes the increase in demand that it experienced for its products in the first quarter in its business-to-business channels due to the COVID-19 PHE may be limited or demand may decline in the future as new COPD patient referrals could decline as physician offices are limiting patient interactions. Given the increased uncertainty around the scope, duration, and impact of the COVID-19 PHE as well as revenue mix between direct-to-consumer and business-to-business channels, Inogen cannot estimate the overall impact to its operations and financial results, which could be material. Due to these uncertainties, the Company is implementing cost savings by delaying certain personnel hires and reducing advertising spend, while also increasing rental setups to improve lead utilization.

ShowHide Related Items >><<
INGN Inogen
$52.76 /

+2.47 (+4.91%)

01/13/20 William Blair
Inogen's softer than expected DTC demand a surprise, says William Blair
11/06/19 Needham
Inogen upgraded to Buy from Hold at Needham
11/06/19 Needham
Inogen upgraded to Buy from Hold at Needham
09/12/19 Piper Sandler
Piper confident in Inogen's double-digit growth potential for 2020
Earnings
Inogen reports Q EPS (7c), consensus (10c) » 16:32
05/05/20
05/05
16:32
05/05/20
16:32
INGN

Inogen

$52.76 /

+2.47 (+4.91%)

Reports Q1 revenue…

Reports Q1 revenue $88.5M, consensus $82.33M. Q1 Adjusted EBITDA for the three months ended March 31, 2020 declined to $4.1 million, or 4.6% of revenue, down from $11.1 million, or 12.3% of revenue, in the comparative period in 2019. The reduction in first quarter 2020 Adjusted EBITDA margin compared to the first quarter of 2019 was primarily due to lower gross profit.

ShowHide Related Items >><<
INGN Inogen
$52.76 /

+2.47 (+4.91%)

01/13/20 William Blair
Inogen's softer than expected DTC demand a surprise, says William Blair
11/06/19 Needham
Inogen upgraded to Buy from Hold at Needham
11/06/19 Needham
Inogen upgraded to Buy from Hold at Needham
09/12/19 Piper Sandler
Piper confident in Inogen's double-digit growth potential for 2020
Over a month ago
Hot Stocks
IntriCon appoints Heather Rider to board of directors » 08:09
03/19/20
03/19
08:09
03/19/20
08:09
IIN

IntriCon

$10.91 /

-1.98 (-15.36%)

, INGN

Inogen

$32.49 /

-5.23 (-13.87%)

IntriCon Corporation…

IntriCon Corporation (IIN) announced the appointment of Heather Rider to the company's Board of Directors, effective March 20, 2020. She is currently a Director of Inogen (INGN) and serves as Chair, Compensation, Nominating and Governance Committee.

ShowHide Related Items >><<
IIN IntriCon
$10.91 /

-1.98 (-15.36%)

01/08/20 B. Riley FBR
B. Riley FBR highlights six Specialty Pharma stocks for 2020
09/20/19 Dougherty
IntriCon initiated with a Buy at Dougherty
03/29/19 Stifel
IntriCon added to Select List at Stifel
INGN Inogen
$32.49 /

-5.23 (-13.87%)

01/13/20 William Blair
Inogen's softer than expected DTC demand a surprise, says William Blair
11/06/19 Needham
Inogen upgraded to Buy from Hold at Needham
11/06/19 Needham
Inogen upgraded to Buy from Hold at Needham
09/12/19 Piper Sandler
Piper confident in Inogen's double-digit growth potential for 2020
Conference/Events
SVB Leerink to hold a conference » 04:55
02/27/20
02/27
04:55
02/27/20
04:55
ABBV

AbbVie

$88.40 /

-0.73 (-0.82%)

, BBIO

BridgeBio

$32.67 /

+0.72 (+2.25%)

, CYAD

Celyad

$9.78 /

-0.17 (-1.71%)

, DCPH

Deciphera

$54.35 /

+0.495 (+0.92%)

, FULC

Fulcrum Therapeutics

$18.50 /

+2.28 (+14.06%)

, GH

Guardant Health

$81.52 /

+5.75 (+7.59%)

, IMVT

Immunovant

$14.87 /

+0.015 (+0.10%)

, INGN

Inogen

$47.88 /

+5.92 (+14.11%)

, LMAT

LeMaitre

$29.53 /

-0.35 (-1.17%)

, NUAN

Nuance

$22.27 /

+0.17 (+0.77%)

, NVCN

Neovasc

$2.70 /

+0.04 (+1.50%)

, RARE

Ultragenyx

$55.71 /

+0.88 (+1.60%)

, QURE

uniQure

$53.57 /

-0.96 (-1.76%)

, SELB

Selecta Biosciences

$4.21 /

+0.215 (+5.38%)

, VCEL

Vericel

$15.06 /

-1.645 (-9.85%)

, RDUS

Radius Health

$17.87 /

-0.06 (-0.33%)

, PODD

Insulet

$180.00 /

-17.03 (-8.64%)

, RDHL

RedHill Biopharma

$4.68 /

+0.12 (+2.63%)

, TCRR

TCR2 Therapeutics

$13.67 /

+0.36 (+2.70%)

, ORGO

Organogenesis

$4.23 /

-0.14 (-3.20%)

, OSMT

Osmotica Pharmaceuticals

$5.45 /

+0.32 (+6.24%)

, MLND

Millendo Therapeutics

$8.75 /

+0.08 (+0.92%)

, ITCI

Intra-Cellular

$22.24 /

-0.79 (-3.43%)

, IFRX

InflaRx

$4.84 /

+0.69 (+16.63%)

, STSA

Satsuma Pharmaceuticals

$26.10 /

-0.22 (-0.84%)

, MIRM

Mirum Pharmaceuticals

$16.53 /

-0.81 (-4.67%)

9th Annual Global…

9th Annual Global Healthcare Conference will be held in New York on February 25-27.

ShowHide Related Items >><<
ABBV AbbVie
$88.40 /

-0.73 (-0.82%)

02/18/20 Cowen
AbbVie price target raised to $105 from $98 at Cowen
02/14/20 Piper Sandler
Piper says Ubrelvy prescription trajectory bodes well for Biohaven's rimegepant
02/11/20 SunTrust
Allergan price target raised to $202 from $194 at SunTrust
02/10/20 Mizuho
AbbVie price target raised to $104 from $96 at Mizuho
BBIO BridgeBio
$32.67 /

+0.72 (+2.25%)

02/19/20
Fly Intel: Top five analyst initiations
02/19/20 Mizuho
Mizuho starts BridgeBio with Buy rating, $51 price target
02/18/20 Mizuho
BridgeBio initiated with a Buy at Mizuho
01/07/20 Raymond James
BridgeBio price target raised to $40 from $36 at Raymond James
CYAD Celyad
$9.78 /

-0.17 (-1.71%)

07/05/19 H.C. Wainwright
Celyad target lowered to $48 on new launch timeline at H.C. Wainwright
07/05/19 Piper Sandler
Celyad price target lowered to $25 from $41 at Piper Jaffray
06/17/19 SunTrust
Celyad selloff a buying opportunity, says SunTrust
06/17/19 Piper Sandler
Piper Jaffray reiterates Overweight on Celyad after EHA update
DCPH Deciphera
$54.35 /

+0.495 (+0.92%)

02/24/20 Jefferies
Epizyme, Blueprint among cancer companies that fit M&A criteria, says Jefferies
02/20/20 Piper Sandler
Deciphera 20% selloff brings 'great entry point,' says Piper Sandler
01/24/20 SVB Leerink
Blueprint Medicines' Ayvakit added to NCCN guidelines, says SVB Leerink
01/22/20 Piper Sandler
Piper Sandler says 'incrementally positive' on Deciphera
FULC Fulcrum Therapeutics
$18.50 /

+2.28 (+14.06%)

12/24/19 H.C. Wainwright
Fulcrum 2020 data may support accelerated approval, says H.C. Wainwright
10/03/19 H.C. Wainwright
Fulcrum Therapeutics initiated with a Buy at H.C. Wainwright
08/12/19 Morgan Stanley
Fulcrum Therapeutics initiated with an Overweight at Morgan Stanley
08/12/19 BofA
Fulcrum Therapeutics initiated with a Buy at BofA/Merrill
GH Guardant Health
$81.52 /

+5.75 (+7.59%)

02/21/20
Fly Intel: Top five analyst initiations
02/21/20 Guggenheim
Guggenheim starts Guardant Health at Buy with addressable market seen expanding
02/21/20 Guggenheim
Guardant Health initiated with a Buy at Guggenheim
01/09/20 JPMorgan
Danaher, Thermo named JPMorgan's top 2020 picks in Life Science Tools
IMVT Immunovant
$14.87 /

+0.015 (+0.10%)

02/24/20
Fly Intel: Top five analyst initiations
02/24/20 SVB Leerink
Immunovant initiated with an Outperform at SVB Leerink
02/05/20
Fly Intel: Top five analyst initiations
02/05/20 Nomura Instinet
Immunovant initiated with a Buy at Nomura Instinet
INGN Inogen
$47.88 /

+5.92 (+14.11%)

01/13/20 William Blair
Inogen's softer than expected DTC demand a surprise, says William Blair
11/06/19 Needham
Inogen upgraded to Buy from Hold at Needham
11/06/19 Needham
Inogen upgraded to Buy from Hold at Needham
09/12/19 Piper Sandler
Piper confident in Inogen's double-digit growth potential for 2020
LMAT LeMaitre
$29.53 /

-0.35 (-1.17%)

10/24/19 Lake Street
Lake Street upgrades LeMaitre to Buy, boosts target to $40 from $34
10/24/19 Lake Street
LeMaitre upgraded to Buy from Hold at Lake Street
10/24/19 First Analysis
LeMaitre downgraded to Outperform from Strong Buy at First Analysis
10/14/19 First Analysis
LeMaitre upgraded to Strong Buy from Outperform at First Analysis
NUAN Nuance
$22.27 /

+0.17 (+0.77%)

01/13/20 Morgan Stanley
Morgan Stanley upgrades Nuance to Overweight on path to double-digit EPS growth
01/13/20 Morgan Stanley
Nuance upgraded to Overweight from Equal Weight at Morgan Stanley
10/02/19 Evercore ISI
Cerence initiated with an Outperform at Evercore ISI
10/01/19 Raymond James
Cerence initiated with a Strong Buy at Raymond James
NVCN Neovasc
$2.70 /

+0.04 (+1.50%)

10/24/19 H.C. Wainwright
Neovasc initiated with a Buy at H.C. Wainwright
03/22/19 Canaccord
Neovasc court win in Germany removes overhang, says Canaccord
RARE Ultragenyx
$55.71 /

+0.88 (+1.60%)

01/10/20 SunTrust
Ultragenyx price target raised to $80 from $75 at SunTrust
01/10/20 Piper Sandler
Ultragenyx gene therapy update 'surprisingly positive,' says Piper Sandler
12/18/19 Piper Sandler
Piper remains buyer of Ultragenyx after Royalty Pharma deal
11/27/19 Cowen
Ultragenyx weakness a buying opportunity, says Cowen
QURE uniQure
$53.57 /

-0.96 (-1.76%)

01/23/20 Cantor Fitzgerald
Cantor sees further upside in uniQure, calls 'highly attractive' buyout candiate
12/10/19 Mizuho
uniQure price target raised to $90 from $67 at Mizuho
12/09/19 Piper Sandler
Piper says uniQure solidified 'front runner' position in Hemophilia B at ASH
12/09/19 H.C. Wainwright
uniQure has 'best in class' hemophilia B profile, says H.C. Wainwright
SELB Selecta Biosciences
$4.21 /

+0.215 (+5.38%)

02/21/20 Cantor Fitzgerald
Selecta positioned for 50%-100% rally on positive data, says Cantor Fitzgerald
02/18/20 Mizuho
Selecta Biosciences price target raised to $7 from $4 at Mizuho
01/29/20
Fly Intel: Top five analyst initiations
01/29/20 Cantor Fitzgerald
Cantor starts 'under the radar' Selecta Biosciences with Overweight rating
VCEL Vericel
$15.06 /

-1.645 (-9.85%)

10/09/19 H.C. Wainwright
Vericel initiated with a Buy rating at H.C. Wainwright
08/26/19 Credit Suisse
Organogenesis reinstated with an Outperform at Credit Suisse
08/14/19 Oppenheimer
MediWound price target lowered to $7 from $15 at Oppenheimer
05/07/19 Oppenheimer
Vericel price target raised to $32 from $23 at Oppenheimer
RDUS Radius Health
$17.87 /

-0.06 (-0.33%)

11/06/19 SVB Leerink
Radius Health price target lowered to $35 from $49 at SVB Leerink
08/29/19 Citi
Radius Health upgraded to Buy from Neutral at Citi
05/30/19 Citi
Radius Health assumed with a Neutral at Citi
05/29/19 Goldman Sachs
Radius Health upgraded to Buy from Neutral at Goldman Sachs
PODD Insulet
$180.00 /

-17.03 (-8.64%)

02/26/20 Cowen
Insulet weakness a buying opportunity, says Cowen
02/26/20 Raymond James
Insulet price target lowered to $205 from $213 at Raymond James
02/26/20 Piper Sandler
Insulet should be bought on selloff from guidance, says Piper Sandler
02/19/20 Piper Sandler
New partnerships expected, but positive, for Insulet, says Piper Sandler
RDHL RedHill Biopharma
$4.68 /

+0.12 (+2.63%)

07/12/19 WBB Securities
RedHill Biopharma upgraded to Strong Buy from Buy at WBB Securities
03/12/19
Fly Intel: Top five analyst upgrades
03/12/19 WBB Securities
RedHill Biopharma upgraded to Buy from Hold at WBB Securities
02/27/19 H.C. Wainwright
RedHill Biopharma price target lowered to $16 from $36 at H.C. Wainwright
TCRR TCR2 Therapeutics
$13.67 /

+0.36 (+2.70%)

11/04/19 H.C. Wainwright
TCR2 Therapeutics initiated with a Buy at H.C. Wainwright
05/31/19 Roth Capital
TCR2 Therapeutics initiated with a Neutral at Roth Capital
03/11/19
Fly Intel: Top five analyst initiations
03/11/19 SVB Leerink
TCR2 Therapeutics initiated with an Outperform at SVB Leerink
ORGO Organogenesis
$4.23 /

-0.14 (-3.20%)

01/10/20 SVB Leerink
Organogenesis initiated with an Outperform at SVB Leerink
05/02/19 Credit Suisse
Organogenesis initiated with an Outperform at Credit Suisse
04/17/19
Fly Intel: Top five analyst initiations
OSMT Osmotica Pharmaceuticals
$5.45 /

+0.32 (+6.24%)

01/22/20 Wells Fargo
Revance, Amphastar named top 2020 Specialty Pharmaceuticals ideas at Wells Fargo
08/12/19 Jefferies
Osmotica shares discounting late-stage pipeline, says Jefferies
06/11/19 Barclays
Osmotica Pharmaceuticals transferred with an Overweight rating at Barclays
03/28/19 Wells Fargo
Wells Fargo cuts Osmotica target to $14 after 'disappointing' study results
MLND Millendo Therapeutics
$8.75 /

+0.08 (+0.92%)

01/10/20 Roth Capital
Millendo Therapeutics initiated with a Buy at Roth Capital
09/16/19 Jefferies
Millendo Therapeutics assumed with a Buy at Jefferies
07/19/19 Wedbush
Millendo Therapeutics initiated with an Outperform at Wedbush
07/18/19 Wedbush
Millendo Therapeutics initiated with an Outperform at Wedbush
ITCI Intra-Cellular
$22.24 /

-0.79 (-3.43%)

02/20/20
Fly Intel: Top five analyst initiations
02/19/20 Evercore ISI
Intra-Cellular initiated with an Outperform at Evercore ISI
02/18/20 Cantor Fitzgerald
Intra-Cellular price target raised to $47 from $43 at Cantor Fitzgerald
01/31/20 JPMorgan
Intra-Cellular downgraded to Neutral on high Caplyta expectations at JPMorgan
IFRX InflaRx
$4.84 /

+0.69 (+16.63%)

07/19/19 Raymond James
InflaRx should not proceed with IFX-1 in HS, says Raymond James
06/06/19 Raymond James
ChemoCentryx price target lowered to $17 from $24 at Raymond James
06/05/19
InflaRx downgraded to Market Perform on HS study results at Raymond James
06/05/19 Piper Sandler
Piper Jaffray cuts ChemoCentryx target to $17 after InflaRx failure
STSA Satsuma Pharmaceuticals
$26.10 /

-0.22 (-0.84%)

02/05/20 Mizuho
Satsuma Pharmaceuticals initiated with a Buy at Mizuho
02/05/20 Mizuho
Satsuma Pharmaceuticals initiated with a Buy at Mizuho
10/08/19 SVB Leerink
Satsuma Pharmaceuticals initiated with an Outperform at SVB Leerink
10/08/19 Credit Suisse
Satsuma Pharmaceuticals initiated with an Outperform at Credit Suisse
MIRM Mirum Pharmaceuticals
$16.53 /

-0.81 (-4.67%)

12/17/19 Citi
Mirum Pharmaceuticals price target raised to $30 from $21 at Citi
12/16/19 Roth Capital
Mirum update shortens development timeframe by two years, says Roth Capital
08/12/19
Fly Intel: Top five analyst initiations
08/12/19 Raymond James
Mirum Pharmaceuticals initiated with an Outperform at Raymond James
Over a quarter ago
Conference/Events
SVB Leerink to hold a conference » 04:55
02/26/20
02/26
04:55
02/26/20
04:55
ABBV

AbbVie

$89.13 /

-4.01 (-4.31%)

, BBIO

BridgeBio

$31.95 /

-1.3 (-3.91%)

, CYAD

Celyad

$9.95 /

+ (+0.00%)

, DCPH

Deciphera

$53.86 /

+0.055 (+0.10%)

, FULC

Fulcrum Therapeutics

$16.22 /

-0.09 (-0.55%)

, GH

Guardant Health

$75.77 /

-8.32 (-9.89%)

, IMVT

Immunovant

$14.86 /

+0.055 (+0.37%)

, INGN

Inogen

$41.96 /

-1.54 (-3.54%)

, LMAT

LeMaitre

$29.88 /

-0.22 (-0.73%)

, NUAN

Nuance

$22.10 /

-0.73 (-3.20%)

, NVCN

Neovasc

$2.66 /

-0.21 (-7.32%)

, RARE

Ultragenyx

$54.83 /

-2.26 (-3.96%)

, QURE

uniQure

$54.53 /

-3.85 (-6.59%)

, SELB

Selecta Biosciences

$4.00 /

-0.225 (-5.33%)

, VCEL

Vericel

$16.71 /

-2.22 (-11.73%)

, RDUS

Radius Health

$17.93 /

-1.05 (-5.53%)

, PODD

Insulet

$197.03 /

-10.46 (-5.04%)

, RDHL

RedHill Biopharma

$4.56 /

-0.15 (-3.18%)

, TCRR

TCR2 Therapeutics

$13.31 /

-0.37 (-2.70%)

, ORGO

Organogenesis

$4.37 /

-0.13 (-2.89%)

, OSMT

Osmotica Pharmaceuticals

$5.13 /

-0.46 (-8.23%)

, MLND

Millendo Therapeutics

$8.67 /

-0.8 (-8.45%)

, ITCI

Intra-Cellular

$23.03 /

-0.02 (-0.09%)

, IFRX

InflaRx

$4.15 /

-0.1 (-2.35%)

, STSA

Satsuma Pharmaceuticals

$26.32 /

-0.22 (-0.83%)

, MIRM

Mirum Pharmaceuticals

$17.34 /

-1 (-5.45%)

9th Annual Global…

9th Annual Global Healthcare Conference will be held in New York on February 25-27.

ShowHide Related Items >><<
ABBV AbbVie
$89.13 /

-4.01 (-4.31%)

02/18/20 Cowen
AbbVie price target raised to $105 from $98 at Cowen
02/14/20 Piper Sandler
Piper says Ubrelvy prescription trajectory bodes well for Biohaven's rimegepant
02/11/20 SunTrust
Allergan price target raised to $202 from $194 at SunTrust
02/10/20 Mizuho
AbbVie price target raised to $104 from $96 at Mizuho
BBIO BridgeBio
$31.95 /

-1.3 (-3.91%)

02/19/20
Fly Intel: Top five analyst initiations
02/19/20 Mizuho
Mizuho starts BridgeBio with Buy rating, $51 price target
02/18/20 Mizuho
BridgeBio initiated with a Buy at Mizuho
01/07/20 Raymond James
BridgeBio price target raised to $40 from $36 at Raymond James
CYAD Celyad
$9.95 /

+ (+0.00%)

07/05/19 H.C. Wainwright
Celyad target lowered to $48 on new launch timeline at H.C. Wainwright
07/05/19 Piper Sandler
Celyad price target lowered to $25 from $41 at Piper Jaffray
06/17/19 SunTrust
Celyad selloff a buying opportunity, says SunTrust
06/17/19 Piper Sandler
Piper Jaffray reiterates Overweight on Celyad after EHA update
DCPH Deciphera
$53.86 /

+0.055 (+0.10%)

02/24/20 Jefferies
Epizyme, Blueprint among cancer companies that fit M&A criteria, says Jefferies
02/20/20 Piper Sandler
Deciphera 20% selloff brings 'great entry point,' says Piper Sandler
01/24/20 SVB Leerink
Blueprint Medicines' Ayvakit added to NCCN guidelines, says SVB Leerink
01/22/20 Piper Sandler
Piper Sandler says 'incrementally positive' on Deciphera
FULC Fulcrum Therapeutics
$16.22 /

-0.09 (-0.55%)

12/24/19 H.C. Wainwright
Fulcrum 2020 data may support accelerated approval, says H.C. Wainwright
10/03/19 H.C. Wainwright
Fulcrum Therapeutics initiated with a Buy at H.C. Wainwright
08/12/19 Morgan Stanley
Fulcrum Therapeutics initiated with an Overweight at Morgan Stanley
08/12/19 BofA
Fulcrum Therapeutics initiated with a Buy at BofA/Merrill
GH Guardant Health
$75.77 /

-8.32 (-9.89%)

02/21/20
Fly Intel: Top five analyst initiations
02/21/20 Guggenheim
Guggenheim starts Guardant Health at Buy with addressable market seen expanding
02/21/20 Guggenheim
Guardant Health initiated with a Buy at Guggenheim
01/09/20 JPMorgan
Danaher, Thermo named JPMorgan's top 2020 picks in Life Science Tools
IMVT Immunovant
$14.86 /

+0.055 (+0.37%)

02/24/20
Fly Intel: Top five analyst initiations
02/24/20 SVB Leerink
Immunovant initiated with an Outperform at SVB Leerink
02/05/20
Fly Intel: Top five analyst initiations
02/05/20 Nomura Instinet
Immunovant initiated with a Buy at Nomura Instinet
INGN Inogen
$41.96 /

-1.54 (-3.54%)

01/13/20 William Blair
Inogen's softer than expected DTC demand a surprise, says William Blair
11/06/19 Needham
Inogen upgraded to Buy from Hold at Needham
11/06/19 Needham
Inogen upgraded to Buy from Hold at Needham
09/12/19 Piper Sandler
Piper confident in Inogen's double-digit growth potential for 2020
LMAT LeMaitre
$29.88 /

-0.22 (-0.73%)

10/24/19 Lake Street
Lake Street upgrades LeMaitre to Buy, boosts target to $40 from $34
10/24/19 Lake Street
LeMaitre upgraded to Buy from Hold at Lake Street
10/24/19 First Analysis
LeMaitre downgraded to Outperform from Strong Buy at First Analysis
10/14/19 First Analysis
LeMaitre upgraded to Strong Buy from Outperform at First Analysis
NUAN Nuance
$22.10 /

-0.73 (-3.20%)

01/13/20 Morgan Stanley
Morgan Stanley upgrades Nuance to Overweight on path to double-digit EPS growth
01/13/20 Morgan Stanley
Nuance upgraded to Overweight from Equal Weight at Morgan Stanley
10/02/19 Evercore ISI
Cerence initiated with an Outperform at Evercore ISI
10/01/19 Raymond James
Cerence initiated with a Strong Buy at Raymond James
NVCN Neovasc
$2.66 /

-0.21 (-7.32%)

10/24/19 H.C. Wainwright
Neovasc initiated with a Buy at H.C. Wainwright
03/22/19 Canaccord
Neovasc court win in Germany removes overhang, says Canaccord
RARE Ultragenyx
$54.83 /

-2.26 (-3.96%)

01/10/20 SunTrust
Ultragenyx price target raised to $80 from $75 at SunTrust
01/10/20 Piper Sandler
Ultragenyx gene therapy update 'surprisingly positive,' says Piper Sandler
12/18/19 Piper Sandler
Piper remains buyer of Ultragenyx after Royalty Pharma deal
11/27/19 Cowen
Ultragenyx weakness a buying opportunity, says Cowen
QURE uniQure
$54.53 /

-3.85 (-6.59%)

01/23/20 Cantor Fitzgerald
Cantor sees further upside in uniQure, calls 'highly attractive' buyout candiate
12/10/19 Mizuho
uniQure price target raised to $90 from $67 at Mizuho
12/09/19 Piper Sandler
Piper says uniQure solidified 'front runner' position in Hemophilia B at ASH
12/09/19 H.C. Wainwright
uniQure has 'best in class' hemophilia B profile, says H.C. Wainwright
SELB Selecta Biosciences
$4.00 /

-0.225 (-5.33%)

02/21/20 Cantor Fitzgerald
Selecta positioned for 50%-100% rally on positive data, says Cantor Fitzgerald
02/18/20 Mizuho
Selecta Biosciences price target raised to $7 from $4 at Mizuho
01/29/20
Fly Intel: Top five analyst initiations
01/29/20 Cantor Fitzgerald
Cantor starts 'under the radar' Selecta Biosciences with Overweight rating
VCEL Vericel
$16.71 /

-2.22 (-11.73%)

10/09/19 H.C. Wainwright
Vericel initiated with a Buy rating at H.C. Wainwright
08/26/19 Credit Suisse
Organogenesis reinstated with an Outperform at Credit Suisse
08/14/19 Oppenheimer
MediWound price target lowered to $7 from $15 at Oppenheimer
05/07/19 Oppenheimer
Vericel price target raised to $32 from $23 at Oppenheimer
RDUS Radius Health
$17.93 /

-1.05 (-5.53%)

11/06/19 SVB Leerink
Radius Health price target lowered to $35 from $49 at SVB Leerink
08/29/19 Citi
Radius Health upgraded to Buy from Neutral at Citi
05/30/19 Citi
Radius Health assumed with a Neutral at Citi
05/29/19 Goldman Sachs
Radius Health upgraded to Buy from Neutral at Goldman Sachs
PODD Insulet
$197.03 /

-10.46 (-5.04%)

02/19/20 Piper Sandler
New partnerships expected, but positive, for Insulet, says Piper Sandler
02/13/20 Piper Sandler
Insulet medical device correction will not impact growth, says Piper Sandler
02/06/20 Raymond James
Insulet price target raised to $213 from $158 at Raymond James
01/07/20 Cowen
Cowen sees minimal Q4 earnings risk for diabetes device stocks
RDHL RedHill Biopharma
$4.56 /

-0.15 (-3.18%)

07/12/19 WBB Securities
RedHill Biopharma upgraded to Strong Buy from Buy at WBB Securities
03/12/19
Fly Intel: Top five analyst upgrades
03/12/19 WBB Securities
RedHill Biopharma upgraded to Buy from Hold at WBB Securities
02/27/19 H.C. Wainwright
RedHill Biopharma price target lowered to $16 from $36 at H.C. Wainwright
TCRR TCR2 Therapeutics
$13.31 /

-0.37 (-2.70%)

11/04/19 H.C. Wainwright
TCR2 Therapeutics initiated with a Buy at H.C. Wainwright
05/31/19 Roth Capital
TCR2 Therapeutics initiated with a Neutral at Roth Capital
03/11/19
Fly Intel: Top five analyst initiations
03/11/19 SVB Leerink
TCR2 Therapeutics initiated with an Outperform at SVB Leerink
ORGO Organogenesis
$4.37 /

-0.13 (-2.89%)

01/10/20 SVB Leerink
Organogenesis initiated with an Outperform at SVB Leerink
05/02/19 Credit Suisse
Organogenesis initiated with an Outperform at Credit Suisse
04/17/19
Fly Intel: Top five analyst initiations
OSMT Osmotica Pharmaceuticals
$5.13 /

-0.46 (-8.23%)

01/22/20 Wells Fargo
Revance, Amphastar named top 2020 Specialty Pharmaceuticals ideas at Wells Fargo
08/12/19 Jefferies
Osmotica shares discounting late-stage pipeline, says Jefferies
06/11/19 Barclays
Osmotica Pharmaceuticals transferred with an Overweight rating at Barclays
03/28/19 Wells Fargo
Wells Fargo cuts Osmotica target to $14 after 'disappointing' study results
MLND Millendo Therapeutics
$8.67 /

-0.8 (-8.45%)

01/10/20 Roth Capital
Millendo Therapeutics initiated with a Buy at Roth Capital
09/16/19 Jefferies
Millendo Therapeutics assumed with a Buy at Jefferies
07/19/19 Wedbush
Millendo Therapeutics initiated with an Outperform at Wedbush
07/18/19 Wedbush
Millendo Therapeutics initiated with an Outperform at Wedbush
ITCI Intra-Cellular
$23.03 /

-0.02 (-0.09%)

02/20/20
Fly Intel: Top five analyst initiations
02/19/20 Evercore ISI
Intra-Cellular initiated with an Outperform at Evercore ISI
02/18/20 Cantor Fitzgerald
Intra-Cellular price target raised to $47 from $43 at Cantor Fitzgerald
01/31/20 JPMorgan
Intra-Cellular downgraded to Neutral on high Caplyta expectations at JPMorgan
IFRX InflaRx
$4.15 /

-0.1 (-2.35%)

07/19/19 Raymond James
InflaRx should not proceed with IFX-1 in HS, says Raymond James
06/06/19 Raymond James
ChemoCentryx price target lowered to $17 from $24 at Raymond James
06/05/19
InflaRx downgraded to Market Perform on HS study results at Raymond James
06/05/19 Piper Sandler
Piper Jaffray cuts ChemoCentryx target to $17 after InflaRx failure
STSA Satsuma Pharmaceuticals
$26.32 /

-0.22 (-0.83%)

02/05/20 Mizuho
Satsuma Pharmaceuticals initiated with a Buy at Mizuho
02/05/20 Mizuho
Satsuma Pharmaceuticals initiated with a Buy at Mizuho
10/08/19 SVB Leerink
Satsuma Pharmaceuticals initiated with an Outperform at SVB Leerink
10/08/19 Credit Suisse
Satsuma Pharmaceuticals initiated with an Outperform at Credit Suisse
MIRM Mirum Pharmaceuticals
$17.34 /

-1 (-5.45%)

12/17/19 Citi
Mirum Pharmaceuticals price target raised to $30 from $21 at Citi
12/16/19 Roth Capital
Mirum update shortens development timeframe by two years, says Roth Capital
08/12/19
Fly Intel: Top five analyst initiations
08/12/19 Raymond James
Mirum Pharmaceuticals initiated with an Outperform at Raymond James
Earnings
Inogen sees net loss in Q1, consensus estimate 18c » 16:15
02/25/20
02/25
16:15
02/25/20
16:15
INGN

Inogen

$41.96 /

-1.54 (-3.54%)

Inogen said, "While…

Inogen said, "While the Company does not give quarterly guidance, the Company does expect to have a net loss in the first quarter of 2020. The Company still expects a GAAP effective tax rate of approximately 25%. Net income guidance also assumes $7.8 million in estimated New Aera intangible amortization expense recorded in research and development expense in 2020 compared to $2.9 million in 2019."

ShowHide Related Items >><<
INGN Inogen
$41.96 /

-1.54 (-3.54%)

01/13/20 William Blair
Inogen's softer than expected DTC demand a surprise, says William Blair
11/06/19 Needham
Inogen upgraded to Buy from Hold at Needham
11/06/19 Needham
Inogen upgraded to Buy from Hold at Needham
09/12/19 Piper Sandler
Piper confident in Inogen's double-digit growth potential for 2020
Hot Stocks
Inogen sees positive cash flow for 2020, no additional equity capital » 16:14
02/25/20
02/25
16:14
02/25/20
16:14
INGN

Inogen

$41.91 /

-1.59 (-3.66%)

The company said,…

The company said, "Inogen expects net positive cash flow for 2020 with no additional equity capital required to meet its current operating plan."

ShowHide Related Items >><<
INGN Inogen
$41.91 /

-1.59 (-3.66%)

01/13/20 William Blair
Inogen's softer than expected DTC demand a surprise, says William Blair
11/06/19 Needham
Inogen upgraded to Buy from Hold at Needham
11/06/19 Needham
Inogen upgraded to Buy from Hold at Needham
09/12/19 Piper Sandler
Piper confident in Inogen's double-digit growth potential for 2020
Earnings
Inogen lowers 2020 net income guidance to $14M-$18M from $25M-$27M » 16:14
02/25/20
02/25
16:14
02/25/20
16:14
INGN

Inogen

$41.91 /

-1.59 (-3.66%)

Inogen is maintaining its…

Inogen is maintaining its 2020 total revenue guidance range of $385M to $400M, representing growth of 6.4% to 10.5% versus 2019 full year results. The consensus estimate is $403.47M. Inogen still expects direct-to-consumer sales to be its fastest growing channel with domestic and international business-to-business sales to have a solid growth rate. Inogen expects rental revenue to grow modestly in 2020 compared to 2019, primarily due to an expected increase in patients on service as well as the low, single-digit percent rate increase in 2020 for Medicare beneficiaries. The company also expects minimal contribution of the Inogen Tidal Assist Ventilator for revenue in both the domestic business-to-business and direct-to-consumer channels in 2020. It added, "This decrease in net income guidance is primarily due to lower revenue estimates than previously expected as well as various manufacturing inefficiencies, particularly in the first quarter of 2020. While the Company does not give quarterly guidance, the Company does expect to have a net loss in the first quarter of 2020. The Company still expects a GAAP effective tax rate of approximately 25%. Net income guidance also assumes $7.8 million in estimated New Aera intangible amortization expense recorded in research and development expense in 2020 compared to $2.9 million in 2019."

ShowHide Related Items >><<
INGN Inogen
$41.91 /

-1.59 (-3.66%)

01/13/20 William Blair
Inogen's softer than expected DTC demand a surprise, says William Blair
11/06/19 Needham
Inogen upgraded to Buy from Hold at Needham
11/06/19 Needham
Inogen upgraded to Buy from Hold at Needham
09/12/19 Piper Sandler
Piper confident in Inogen's double-digit growth potential for 2020
Earnings
Inogen reports Q4 EPS (6c), consensus 10c » 16:12
02/25/20
02/25
16:12
02/25/20
16:12
INGN

Inogen

$41.73 /

-1.77 (-4.07%)

Reports Q4 revenue…

Reports Q4 revenue $78.9M, consensus $86.42M. As of December 31, 2019, the company had 329 inside direct-to-consumer sales representatives and 17 outside physician sales representatives. The company said, "While 2019 was a challenging year, revenue increased 8.2% over the prior year, excluding the previously disclosed large national provider who buys through our private label partner, to whom sales decreased $20.4 million from the prior year, and excluding the $3.1 million foreign exchange impact. In addition, we believe we took steps during 2019 to improve our operational execution and financial performance in 2020, including optimizing our direct-to-consumer salesforce, launching the Inogen One G5, and initiating our commercial plan for our newly acquired Tidal Assist Ventilator."

ShowHide Related Items >><<
INGN Inogen
$41.73 /

-1.77 (-4.07%)

01/13/20 William Blair
Inogen's softer than expected DTC demand a surprise, says William Blair
11/06/19 Needham
Inogen upgraded to Buy from Hold at Needham
11/06/19 Needham
Inogen upgraded to Buy from Hold at Needham
09/12/19 Piper Sandler
Piper confident in Inogen's double-digit growth potential for 2020

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.